FR2756297B1 - Procede de production de virus recombinants - Google Patents

Procede de production de virus recombinants

Info

Publication number
FR2756297B1
FR2756297B1 FR9614278A FR9614278A FR2756297B1 FR 2756297 B1 FR2756297 B1 FR 2756297B1 FR 9614278 A FR9614278 A FR 9614278A FR 9614278 A FR9614278 A FR 9614278A FR 2756297 B1 FR2756297 B1 FR 2756297B1
Authority
FR
France
Prior art keywords
producing recombinant
recombinant viruses
producing
concerns
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9614278A
Other languages
English (en)
French (fr)
Other versions
FR2756297A1 (fr
Inventor
Prehaud Helene Leblois
Michel Perricaudet
Emmanuelle Vigne
Patrice Yeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9497899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2756297(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR9614278A priority Critical patent/FR2756297B1/fr
Priority to KR1019997004531A priority patent/KR100719645B1/ko
Priority to BRPI9713388-4A priority patent/BR9713388B1/pt
Priority to IL12968697A priority patent/IL129686A/xx
Priority to AU52261/98A priority patent/AU731106B2/en
Priority to AT97947083T priority patent/ATE317908T1/de
Priority to CA2271438A priority patent/CA2271438C/fr
Priority to EP97947083A priority patent/EP0946741B1/fr
Priority to ES97947083T priority patent/ES2260803T3/es
Priority to CZ19991822A priority patent/CZ293947B6/cs
Priority to JP52328298A priority patent/JP4686670B2/ja
Priority to SK666-99A priority patent/SK286900B6/sk
Priority to DE69735274T priority patent/DE69735274T2/de
Priority to PCT/FR1997/002073 priority patent/WO1998022607A1/fr
Priority to US09/308,398 priority patent/US6387670B1/en
Priority to HU0001762A priority patent/HU224713B1/hu
Priority to ZA9710516A priority patent/ZA9710516B/xx
Publication of FR2756297A1 publication Critical patent/FR2756297A1/fr
Publication of FR2756297B1 publication Critical patent/FR2756297B1/fr
Application granted granted Critical
Priority to NO19992464A priority patent/NO323937B1/no
Priority to US10/141,491 priority patent/US20030022356A1/en
Priority to NO2013009C priority patent/NO2013009I1/no
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pens And Brushes (AREA)
  • Materials For Medical Uses (AREA)
FR9614278A 1996-11-22 1996-11-22 Procede de production de virus recombinants Expired - Lifetime FR2756297B1 (fr)

Priority Applications (20)

Application Number Priority Date Filing Date Title
FR9614278A FR2756297B1 (fr) 1996-11-22 1996-11-22 Procede de production de virus recombinants
JP52328298A JP4686670B2 (ja) 1996-11-22 1997-11-18 組換えウイルスの製造方法
DE69735274T DE69735274T2 (de) 1996-11-22 1997-11-18 Verfahren zur herstellung von rekombinanten viren
IL12968697A IL129686A (en) 1996-11-22 1997-11-18 Method for producing recombinant virus
AU52261/98A AU731106B2 (en) 1996-11-22 1997-11-18 Method for producing recombinant virus
AT97947083T ATE317908T1 (de) 1996-11-22 1997-11-18 Verfahren zur herstellung von rekombinanten viren
CA2271438A CA2271438C (fr) 1996-11-22 1997-11-18 Procede de production de virus recombinants
EP97947083A EP0946741B1 (fr) 1996-11-22 1997-11-18 Procede de production de virus recombinants
ES97947083T ES2260803T3 (es) 1996-11-22 1997-11-18 Procedimiento para la produccion de virus recombinantes.
CZ19991822A CZ293947B6 (cs) 1996-11-22 1997-11-18 Způsob přípravy rekombinantních virů a rekombinantní virus
KR1019997004531A KR100719645B1 (ko) 1996-11-22 1997-11-18 재조합 바이러스 생성방법
SK666-99A SK286900B6 (sk) 1996-11-22 1997-11-18 Spôsob prípravy rekombinantných vírusov a rekombinantný vírus
BRPI9713388-4A BR9713388B1 (pt) 1996-11-22 1997-11-18 processos de produÇço de vÍrus e de adenovÍrus recombinantes defectivos, e baculovÍrus recombinante.
PCT/FR1997/002073 WO1998022607A1 (fr) 1996-11-22 1997-11-18 Procede de production de virus recombinants
US09/308,398 US6387670B1 (en) 1996-11-22 1997-11-18 Method for producing recombinant virus
HU0001762A HU224713B1 (en) 1996-11-22 1997-11-18 Method for producing recombinant virus
ZA9710516A ZA9710516B (en) 1996-11-22 1997-11-21 Process for the production of recombinant viruses.
NO19992464A NO323937B1 (no) 1996-11-22 1999-05-21 Rekombinante hjelpe baculovirus samt fremgangsmate for fremstilling av rekombinante virus.
US10/141,491 US20030022356A1 (en) 1996-11-22 2002-05-09 Method for producing recombinant virus
NO2013009C NO2013009I1 (no) 1996-11-22 2013-04-15 Alipogen tiparvovec

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9614278A FR2756297B1 (fr) 1996-11-22 1996-11-22 Procede de production de virus recombinants

Publications (2)

Publication Number Publication Date
FR2756297A1 FR2756297A1 (fr) 1998-05-29
FR2756297B1 true FR2756297B1 (fr) 1999-01-08

Family

ID=9497899

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9614278A Expired - Lifetime FR2756297B1 (fr) 1996-11-22 1996-11-22 Procede de production de virus recombinants

Country Status (18)

Country Link
US (2) US6387670B1 (enExample)
EP (1) EP0946741B1 (enExample)
JP (1) JP4686670B2 (enExample)
KR (1) KR100719645B1 (enExample)
AT (1) ATE317908T1 (enExample)
AU (1) AU731106B2 (enExample)
BR (1) BR9713388B1 (enExample)
CA (1) CA2271438C (enExample)
CZ (1) CZ293947B6 (enExample)
DE (1) DE69735274T2 (enExample)
ES (1) ES2260803T3 (enExample)
FR (1) FR2756297B1 (enExample)
HU (1) HU224713B1 (enExample)
IL (1) IL129686A (enExample)
NO (2) NO323937B1 (enExample)
SK (1) SK286900B6 (enExample)
WO (1) WO1998022607A1 (enExample)
ZA (1) ZA9710516B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2375119A1 (en) * 1999-05-27 2000-12-07 Genovo, Incorporated Compositions and methods for production of recombinant virus using a carrier vector derived from a nonmammalian virus
US6793926B1 (en) * 1999-05-27 2004-09-21 Genovo, Inc. Methods for production of a recombinant adeno-associated virus
WO2000073424A1 (en) * 1999-05-28 2000-12-07 Mount Sinai School Of Medicine A novel baculovirus/adenovirus hybrid vector for the rescue, production and titration of high-capacity adenovirus amplicon vectors
GB9919409D0 (en) 1999-08-18 1999-10-20 Univ Oxford Brookes Baculovirus expression system
US7897380B2 (en) 2002-08-29 2011-03-01 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
GB0702694D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Vectors
GB0702695D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
EP2019143A1 (en) 2007-07-23 2009-01-28 Genethon CNS gene delivery using peripheral administration of AAV vectors
EP2058401A1 (en) 2007-10-05 2009-05-13 Genethon Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
KR101575696B1 (ko) * 2008-03-05 2015-12-08 카운실 오브 사이언티픽 엔드 인더스트리얼 리서치 고분자 하이브리드막
EP2287323A1 (en) 2009-07-31 2011-02-23 Association Institut de Myologie Widespread gene delivery to the retina using systemic administration of AAV vectors
EP2292781A1 (en) * 2009-08-17 2011-03-09 Genethon Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions
EP2553105B1 (en) * 2010-04-01 2014-12-17 Weidong Xiao Compositions and methods for the production of recombinant virus vectors
WO2011130119A2 (en) 2010-04-14 2011-10-20 Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
EP3470523A1 (en) 2012-05-09 2019-04-17 Oregon Health & Science University Adeno associated virus plasmids and vectors
TWI698240B (zh) 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
US20150182637A1 (en) 2012-06-21 2015-07-02 Association Institut De Myologie Widespread gene delivery of gene therapy vectors
US11078464B2 (en) * 2013-08-30 2021-08-03 Amgen Inc. High titer recombinant AAV vector production in adherent and suspension cells
CN106414474B (zh) 2014-03-17 2021-01-15 阿德夫拉姆生物技术股份有限公司 用于视锥细胞中增强的基因表达的组合物和方法
CA2978068C (en) 2015-03-02 2024-05-28 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
AU2018373279B2 (en) 2017-11-27 2024-07-25 Trames Bio, Inc. Compositions and methods for neurological diseases
BR112020015798A2 (pt) 2018-02-01 2021-03-09 Homology Medicines, Inc. Composições de vírus adeno-associado para restaurar função de gene da pah e métodos de uso das mesmas
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
EP3755795A4 (en) 2018-02-19 2022-07-20 Homology Medicines, Inc. Adeno-associated virus compositions for restoring f8 gene function and methods of use thereof
BR112020022669A2 (pt) 2018-05-08 2021-02-17 Neuracle Science Co., Ltd distribuição de vírus adenoassociado (aav) de anticorpos anti-fam19a5
JP2022523719A (ja) 2019-01-31 2022-04-26 オレゴン・ヘルス・アンド・サイエンス・ユニバーシティ Ａａｖキャプシドの転写依存性定方向進化を使用するための方法
US20220348635A1 (en) 2019-08-21 2022-11-03 Coda Biotherapeutics, Inc. Compositions and methods for neurological diseases
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
EP4225382A4 (en) 2020-10-07 2025-04-23 AskBio Inc. ADMINISTRATION OF THERAPEUTIC ADENO-ASSOCIATED VIRUS FUKKUTIN-ASSOCIATED PROTEIN (FKRP) FOR THE TREATMENT OF DYSTROGLYCANOPATHY. DISORDERS INCLUDING LIMB GIRDLE 21
EP4514845A1 (en) 2022-04-29 2025-03-05 Broadwing Bio LLC Bispecific antibodies and methods of treating ocular disease
AU2023259251A1 (en) 2022-04-29 2024-11-14 Broadwing Bio Llc Angiopoietin-related protein 7-specific antibodies and uses thereof
CN119365485A (zh) 2022-04-29 2025-01-24 博闻生物有限责任公司 补体因子h相关4特异性抗体及其用途
WO2024227154A1 (en) 2023-04-28 2024-10-31 Broadwing Bio Llc Complement component 3 (c3)-specific antibodies and uses thereof
WO2025040613A1 (en) * 2023-08-21 2025-02-27 Vector Biopharma Ag Cell line for production of helper-dependent adenoviruses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005538A1 (en) * 1988-11-14 1990-05-31 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Parvovirus capsids
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
EP0785803A4 (en) * 1994-09-23 2000-08-02 Gen Hospital Corp Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell

Also Published As

Publication number Publication date
KR100719645B1 (ko) 2007-05-17
KR20000057202A (ko) 2000-09-15
NO2013009I1 (no) 2013-04-29
HUP0001762A3 (en) 2002-01-28
IL129686A0 (en) 2000-02-29
NO992464D0 (no) 1999-05-21
CA2271438A1 (fr) 1998-05-28
US20030022356A1 (en) 2003-01-30
CA2271438C (fr) 2010-10-26
ZA9710516B (en) 1998-06-10
DE69735274T2 (de) 2006-10-12
NO992464L (no) 1999-06-23
EP0946741A1 (fr) 1999-10-06
ES2260803T3 (es) 2006-11-01
WO1998022607A1 (fr) 1998-05-28
BR9713388B1 (pt) 2009-01-13
CZ293947B6 (cs) 2004-08-18
IL129686A (en) 2005-12-18
DE69735274D1 (de) 2006-04-20
ATE317908T1 (de) 2006-03-15
AU5226198A (en) 1998-06-10
AU731106B2 (en) 2001-03-22
SK286900B6 (sk) 2009-07-06
JP4686670B2 (ja) 2011-05-25
HU224713B1 (en) 2006-01-30
FR2756297A1 (fr) 1998-05-29
CZ182299A3 (cs) 1999-08-11
EP0946741B1 (fr) 2006-02-15
SK66699A3 (en) 2000-02-14
HUP0001762A2 (hu) 2000-09-28
JP2001503993A (ja) 2001-03-27
US6387670B1 (en) 2002-05-14
BR9713388A (pt) 2000-03-21
NO323937B1 (no) 2007-07-23

Similar Documents

Publication Publication Date Title
FR2756297B1 (fr) Procede de production de virus recombinants
BR9811854B1 (pt) processo de preparação de 3,3-dimetilbutiraldeìdo por oxidação de 3,3-dimetilbutanol.
EP1394259A3 (en) Recombinant infectious non-segmented negative strand RNA virus
DE69827083D1 (de) Vakuumverfahren zur Herstellung von Siloxan-Oxyalkylen-Copolymeren
DE59008015D1 (de) Kathode zur Erzeugung von intensiven, modulierten Ein- oder Mehrkanal-Elektronenstrahlen.
EP0755440A4 (en) NOVEL MUT VIRUSES, ANTIVIRAL COMPOUNDS, AND NOVEL VACCINE PRODUCTION METHODS
BR9000632A (pt) Eletrolisador a diafragma monopolar,processo de eletrolise cloro-alcalina e anodo
ZA992619B (en) Electrolyser for the production of halogen gases.
DK0942992T3 (da) O-fucosyltransferase
FR2686898B1 (fr) Methode de production de la l-phenylalanine.
DE59703846D1 (de) Verfahren zur katalytischen Herstellung von Alkalialkoholaten
DK78990A (da) Fremgangsmaade til rensning af ydre membran protein for haemophilus influenza
NO950807L (no) Fremgangsmåte for fremstilling av karbonelektroder
ES2179908T3 (es) Acidos sacarosamonocarboxilicos acilados.
ATE309371T1 (de) Protein mit dnase-aktivität
WO1997035015A3 (de) Tyrosin-phosphatase-verwandtes protein
DE69837437D1 (de) Gen, polynukleotid, polypeptid und virion des non-b, non-c, non-g-hepatitis virus, eine methode zur abtrennung dieses virions und methoden für die virusdetektion.
DE69938427D1 (de) Tes gen und dessen verwendung
FR2703075B1 (fr) Procede de preparation de diaphragme microporeux.
IT1306132B1 (it) Anodo perfezionato, procedimento per la sua fabbricazione eprocedimento per la produzione di alluminio.
ES8400401A1 (es) "un procedimiento para preparar un 1,4-dialcohilo inferior-3-alcoxicarbonilo inferior-pirrol-2-acetato de alcohilo inferior".
MY130723A (en) Accelerator for the production of polyamides from aminonitriles
EE200100234A (et) PRV-1-geen ja selle kasutamine
WO1997016457A3 (de) Protein mit anti-tumorwirkung
WO1997012969A3 (de) Fmr1-verwandtes protein

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 20